212 related articles for article (PubMed ID: 28711577)
1. A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer.
Park SR; Kim MJ; Nam BH; Kim CG; Lee JY; Cho SJ; Kong SY; Park YI
Eur J Cancer; 2017 Sep; 83():32-42. PubMed ID: 28711577
[TBL] [Abstract][Full Text] [Related]
2. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
3. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.
Yamada Y; Higuchi K; Nishikawa K; Gotoh M; Fuse N; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hamada C; Hyodo I
Ann Oncol; 2015 Jan; 26(1):141-148. PubMed ID: 25316259
[TBL] [Abstract][Full Text] [Related]
4. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Kim ST; Hong YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Lee JW; Jo SJ; Park YS
BMC Cancer; 2014 Nov; 14():883. PubMed ID: 25424120
[TBL] [Abstract][Full Text] [Related]
5. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
[TBL] [Abstract][Full Text] [Related]
7. Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.
Tanioka H; Honda M; Tanaka C; Morita Y; Ishibashi K; Kato T; Matsuda C; Kataoka M; Satake H; Munemoto Y; Kobayashi K; Takahashi M; Nakata K; Sakamoto J; Oba K; Mishima H
Int J Clin Oncol; 2019 Jul; 24(7):836-841. PubMed ID: 30778794
[TBL] [Abstract][Full Text] [Related]
8. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin.
Nishina T; Azuma M; Nishikawa K; Gotoh M; Bando H; Sugimoto N; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Mitome T; Kageyama H; Hyodo I
Gastric Cancer; 2019 Jan; 22(1):138-146. PubMed ID: 29948386
[TBL] [Abstract][Full Text] [Related]
9. Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin.
Nishikawa K; Yamada Y; Ishido K; Gotoh M; Bando H; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hamada C; Hyodo I
Gastric Cancer; 2017 Jul; 20(4):640-645. PubMed ID: 27822684
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Wan Y; Hui H; Wang X; Wu J; Sun S
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial).
Lee KW; Chung IJ; Ryu MH; Park YI; Nam BH; Oh HS; Lee KH; Han HS; Seo BG; Jo JC; Lee HR; Kim JW; Park SR; Cho SH; Kang YK;
Gastric Cancer; 2021 Jan; 24(1):156-167. PubMed ID: 32596783
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of lobaplatin plus S-1 and the predictive value of circulating tumor cell in patients with advanced gastric cancer].
Feng Q; Zhao JR; Zhang AX; Li SL
Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):696-702. PubMed ID: 30293397
[No Abstract] [Full Text] [Related]
13. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
14. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
[TBL] [Abstract][Full Text] [Related]
15. Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
Jiang Z; Zhou A; Sun Y; Zhang W
BMC Cancer; 2022 Mar; 22(1):253. PubMed ID: 35264150
[TBL] [Abstract][Full Text] [Related]
16. A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
Huang D; Ba Y; Xiong J; Xu N; Yan Z; Zhuang Z; Yu Z; Wan H; Zhang Y; Deng T; Zheng R; Guo Z; Hu C; Wang M; Yu Z; Yao Y; Meng J
Eur J Cancer; 2013 Sep; 49(14):2995-3002. PubMed ID: 23810466
[TBL] [Abstract][Full Text] [Related]
17. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
Chibaudel B; Maindrault-Goebel F; Lledo G; Mineur L; André T; Bennamoun M; Mabro M; Artru P; Carola E; Flesch M; Dupuis O; Colin P; Larsen AK; Afchain P; Tournigand C; Louvet C; de Gramont A
J Clin Oncol; 2009 Dec; 27(34):5727-33. PubMed ID: 19786657
[TBL] [Abstract][Full Text] [Related]
18. [Clinical Experience of S-1 and Oxaliplatin(SOX)as the First-Line Chemotherapy for Metastatic/Recurrent Gastric Cancer].
Toyokawa T; Tamura T; Shibutani M; Ohira G; Yamazoe S; Kimura K; Nagahara H; Amano R; Tanaka H; Muguruma K; Yashiro M; Hirakawa K; Ohira M
Gan To Kagaku Ryoho; 2017 May; 44(5):405-408. PubMed ID: 28536336
[TBL] [Abstract][Full Text] [Related]
19. Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy.
Saeki H; Emi Y; Oki E; Tokunaga S; Kakeji Y; Akagi Y; Baba H; Baba E; Maehara Y;
BMC Cancer; 2018 Jan; 18(1):57. PubMed ID: 29310611
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.
Dai X; Zhang X; Wang C; Jiang J; Wu C
Oncotarget; 2017 May; 8(18):30495-30501. PubMed ID: 27911869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
